Publications for Bo Nordenskjöld
Co-author map based on ISI articles 2007-

Publications mentioned in social media 18 times*

Keywords

tumours tumors trial treatment tamoxifen survival recurrence receptor protein prognostic patients grade gene docetaxel control cancer breast benefit adjuvant (hr

Journal Articles

M. Weiner, L Skoog, T Fornander, Bo Nordenskjöld, D C. Sgroi and Olle Stål
  Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
 
Altmetric usage: 9

  Annals of Oncology, 2013, 24(8), 1994-1999.
   Fulltext  PDF  

Anna Gothlin Eremo, Pia Wegman, Olle Stål, Bo Nordenskjöld, Tommy Fornander and Sten Wingren
  Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients
  Oncology Reports, 2013, 29(4), 1467-1474.
 Web of Science® Times Cited: 1

C Oakman, P A. Francis, J Crown, E Quinaux, M Buyse, E De Azambuja, M Margeli Vila, M Andersson, Bo Nordenskjöld, R Jakesz, B Thuerlimann, J Gutierrez, V Harvey, L Punzalan, P DellOrto, D Larsimont, I Steinberg, R D. Gelber, M Piccart-Gebhart, G Viale and A Di Leo
  Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the Breast International Group 02-98 phase III trial
 
Altmetric usage: 3

  Annals of Oncology, 2013, 24(5), 1203-1211.

Helena Fohlin, Gizeh Perez-Tenorio, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld, John Carstensen and Olle Stål
  Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer
 
Altmetric usage: 1

  European Journal of Cancer, 2013, 49(6), 1196-1204.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Johan Rosell, Bo Nordenskjöld, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per-Olof Malmstrom, Arne Wallgren, Olle Stål and John Carstensen
  Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
 
Altmetric usage: 2

  Breast Cancer Research and Treatment, 2013, 138(2), 467-473.
 Web of Science® Times Cited: 1

Josefine Bostner, Elin Karlsson, Muneeswaran J. Pandiyan, Hanna Westman, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
  Breast Cancer Research and Treatment, 2013, 137(2), 397-406.
 Web of Science® Times Cited: 4

Elin Karlsson, Gizeh Pérez-Tenorio, Risul Amin, Josefine Bostner, Lambert Skoog, Tommy Fornander, Dennis C Sgroi, Bo Nordenskjöld, Anna-Lotta Hallbeck and Olle Stål
  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
 
Altmetric usage: 2

  Breast Cancer Research, 2013, 15(5), R96.
   Fulltext  PDF  

Tove Sivik, Cecilia Gunnarsson, Tommy Fornander, Bo Nordenskjöld, Lambert Skoog, Olle Stål and Agneta Jansson
  17β-hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer
  PLoS ONE, 2012, 7(7), e40568.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Gizeh Perez-Tenorio, Elin Karlsson, Marie Ahnström, Birgit Olsson, Birgitta Holmlund, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
  Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer
  Breast Cancer Research and Treatment, 2011, 128(3), 713-723.
   Fulltext  PDF  
 Web of Science® Times Cited: 7

Piiha-Lotta Jerevall, Xiai-Jun Ma, Hongying Li, Ranelle Salunga, Nicole C. Kesty, Mark G. Erlander, Dennis Sgroi, Birgitta Holmlund, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Prognostic utility of HOXB13:IL17BR and Molecular Grade Index in early-stage breast cancer patients from the Stockholm trial
  British Journal of Cancer, 2011, 104(11), 1762-1769.
   Fulltext  PDF  
 Web of Science® Times Cited: 22

Johan Rosell, Bo Nordenskjöld, N-O Bengtsson, T Fornander, T Hatschek, H Lindman, P-O Malmstrom, A Wallgren, Olle Stål and John Carstensen
  Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
  BRITISH JOURNAL OF CANCER, 2011, 104(6), 899-902.
 Web of Science® Times Cited: 2

Mahmoud R Khoshnoud, Britta Lofdahl, Helena Fohlin, Tommy Fornander, Olle Stål, Lambert Skoog, Jonas Bergh and Bo Nordenskjöld
  Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
  Breast Cancer Research and Treatment, 2011, 126(2), 421-430.
 Web of Science® Times Cited: 12

Piiha-Lotta Jerevall, Agneta Jansson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld and Olle Stål
  Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
  Breast Cancer Research, 2010, 12(4), .
 Web of Science® Times Cited: 6

Josefine Bostner, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
  Estrogen Receptor-alpha Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
  Clinical Cancer Research, 2010, 16(5), 1624-1633.
   Fulltext  PDF  
 Web of Science® Times Cited: 17

B. C. Sanchez, M. Sundqvist, Helena Fohlin, F. Spyratos, Bo Nordenskjöld, Olle Stål, B. K and Linderholm
  Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF
  European Journal of Cancer, 2010, 46(9), 1580-1587.
 Web of Science® Times Cited: 4

Ann-Christine Kallstrom, Rebecka Salme, Lisa Ryden, Bo Nordenskjöld, Per-Ebbe Jonsson and Olle Stål
  17 beta-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
  EUROPEAN JOURNAL OF CANCER, 2010, 46(5), 892-900.
 Web of Science® Times Cited: 5

Evandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, Emmanuel Quinaux, John P A Crown, Malou Vicente, Rosa Giuliani, Bo Nordenskjöld, Jorge Gutierez, Michael Andersson, Mireia Margeli Vila, Raimund Jakesz, Jan Demol, Joanna Dewar, Armando Santoro, Ana Lluch, Steven Olsen, Richard D Gelber, Angelo Di Leo and Martine Piccart-Gebhart
  The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
  Breast Cancer Research and Treatment, 2010, 119(1), 145-153.
 Web of Science® Times Cited: 36

K Lundgren, Bo Nordenskjöld and G Landberg
  Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer
 
Altmetric usage: 1

  BRITISH JOURNAL OF CANCER, 2009, 101(10), 1769-1781.
 Web of Science® Times Cited: 36

S. Alkner, P.-O. Bendahl, M. Ferno, Bo Nordenskjöld and L. Ryden
  Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial
  European Journal of Cancer, 2009, 45(14), 2496-2502.
 Web of Science® Times Cited: 13

Agneta Jansson, Lovisa Delander, Cecilia Gunnarsson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld and Olle Stål
  Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
  Clinical Cancer Research, 2009, 15(10), 3610-3616.
 Web of Science® Times Cited: 11

Patrik Johansson, Helena Fohlin, Lars-Gunnar Arnesson, Monika Dufmats, Kerstin Nordenskjoeld, Bo Nordenskjöld and Olle Stål
  Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy
  ACTA ONCOLOGICA, 2009, 48(4), 504-513.
   Fulltext  PDF  
 Web of Science® Times Cited: 2

Allan Hackshaw, Michael Baum, Tommy Fornander, Bo Nordenskjöld, Antonio Nicolucci, Kathryn Monson, Sharon Forsyth, Krystyna Reczko, Ulla Johansson, Helena Fohlin, Miriam Valentini and Richard Sainsbury
  Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
  JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101(5), 341-349.
 Web of Science® Times Cited: 16

Marie Ahnström, Marie Askmalm Stenmark, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
  Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer
  International Journal of Oncology, 2009, 34(2), 441-448.
 Web of Science® Times Cited: 6

Gizeh Perez-Tenorio, Elin Karlsson, Marie Ahnström Waltersson, Birgit Olsson, Birgitta Holmlund, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
  Clinical Value of RPS6KB1 and RPS6KB2 Gene Amplification in Postmenopausal Breast Cancer
  , 2008, , .

Emma Niméus-Malmström, Morten Krogh, Per Malmström, Carina Strand, Irma Fredriksson, Per Karlsson, Bo Nordenskjöld, Olle Stål, Görel Östberg, Carsten Peterson and Marten Ferno
  Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy
  Breast Cancer Research, 2008, 10(2), .
 Web of Science® Times Cited: 19

P Berglund, M Stighall, K Jirström, L Rydén, M Ferno, Bo Nordenskjöld and G Landberg
  Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern
  Journal of Clinical Pathology, 2008, 61(2), 184-191.
 Web of Science® Times Cited: 5

Prudence Francis, John Crown, Angelo Di Leo, Marc Buyse, Ana Balil, Michael Andersson, Bo Nordenskjöld, Istvan Lang, Raimund Jakesz, Daniel Vorobiof, Jorge Gutiérrez, Guy van Hazel, Stella Dolci, Sophie Jamin, Belguendouz Bendahmane, Richard D. Gelber, Aron Goldhirsch, Monica Castiglione-Gertsch and Martine Piccart-Gebhart
  Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial
  Journal of the National Cancer Institute, 2008, 100(2), 121-133.
 Web of Science® Times Cited: 80

Bent Kristensen, Bent Ejlertsen, Henning T. Mouridsen, Maj-Britt Jensen, Jørn Andersen, Brita Bjerregaard, Søren Cold, Per Edlund, Marianne Ewertz, Claus Kamby, Henrik Lindman, Bo Nordenskjöld and Jonas Bergh
  Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
  Acta Oncologica, 2008, 47(4), 740-746.
 Web of Science® Times Cited: 38

B. C. Pestalozzi, P. Francis, E. Quinaux, S. Dolci, E. Azambuja, R. D. Gelber, G. Viale, A. Balil, M. Andersson, Bo Nordenskjöld, M. Gnant, J. Gutierrez, I. Láng, J. P. A. Crown and M. Piccart-Gebhart
  Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial
  Annals of Oncology, 2008, 19(11), 1837-1841.
 Web of Science® Times Cited: 8

Lisa Rydén, Göran Landberg, Olle Stål, Bo Nordenskjöld, Mårten Fernö and Pär-Ola Bendahl
  HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
  Breast Cancer Research and Treatment, 2008, 109(2), 351-357.
 Web of Science® Times Cited: 20

Barbara E. Licznerska, Pia P. Wegman, Bo Nordenskjöld and Sten Wingren
  In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients
  Breast Cancer Research and Treatment, 2008, 112(1), 15-23.
 Web of Science® Times Cited: 7

Cecilia Gunnarsson, Piiha-Lotta Jerevall, Karl Hammar, Birgit Olsson, Bo Nordenskjöld, Agneta Jansson and Olle Stål
  Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer
  Breast Cancer Research and Treatment, 2008, 108(1), 35-41.
 Web of Science® Times Cited: 18

Piiha-Lotta Jerevall, Sara Brommesson, Carina Strand, Sofia Gruvberger-Saal, Per Malmström, Bo Nordenskjöld, Sten Wingren, Peter Söderkvist, Mårten Fernö and Olle Stål
  Exploring the two-gene ratio in breast cancer – independent roles for HOXB13 and IL17BR in prediction of clinical outcome
  Breast Cancer Research and Treatment, 2008, 107(2), 225-234.
   Fulltext  PDF  
 Web of Science® Times Cited: 24

Katja Lundgren, Karolina Holm, Bo Nordenskjöld, Ake Borg and Goran Landberg
  Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
  Breast cancer research, 2008, 10(5), R81.
   Fulltext  PDF  
 Web of Science® Times Cited: 18

Gizeh Pérez-Tenorio, Liza Alkhori, Birgit Olsson, Marie Ahnstro Waltersson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
  Clinical Cancer Research, 2007, 13(12), 3577-3584.
 Web of Science® Times Cited: 109

B. Ejlertsen, H.T. Mouridsen, M.-B. Jensen, J. Andersen, S. Cold, P. Edlund, M. Ewertz, B.B. Jensen, C. Kamby, Bo Nordenskjöld and J. Bergh
  Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
  European Journal of Cancer, 2007, 43(5), 877-884.
 Web of Science® Times Cited: 33

Pia Wegman Palmebäck, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld and Sten Wingren
  Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients
  Breast Cancer Research, 2007, 9(1), R7.
   Fulltext  PDF  
 Web of Science® Times Cited: 143

Karin Söderlund Leifler, Olle ¨, Lambert Skoog, Lars Erik Rutqvist, Bo Nordenskjöld and Marie Stenmark Askmalm
  Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer
  International Journal of Radiation Oncology, Biology, Physics, 2007, 68(1), 50-58.
 Web of Science® Times Cited: 28

Josefine Bostner, Marie Ahnström Waltersson, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stål
  Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
  Oncogene, 2007, 26(49), 6997-7005.
 Web of Science® Times Cited: 46

Gizeh Perez-Tenorio, Fredrik Berglund, Anna Esguerra Merca, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer
  International Journal of Oncology, 2006, 28(5), 1031-1042.
 Web of Science® Times Cited: 22

M. Stendahl, L. Ryden, Bo Nordenskjöld, P.E. Jonsson, G. Landberg and K. Jirstrom
  High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients
  Clinical Cancer Research, 2006, 12(15), 4614-4618.
 Web of Science® Times Cited: 56

A Kronblad, K Jirström, L Rydén, Bo Nordenskjöld and G Landberg
  Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response
  International Journal of Cancer, 2006, 118(10), 2609-2616.
 Web of Science® Times Cited: 39

Cecilia Gunnarsson, Agneta Jansson, Birgitta Holmlund, Lilianne Ferraud, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Expression of COX-2 and steroid converting enzymes in breast cancer
  Oncology Reports, 2006, 16(2), 219-224.
 Web of Science® Times Cited: 6

Pia Wegman (Palmebäck), Olle Stål, Marie Stenmark Askmalm, Bo Nordenskjöld, Lars-Erik Rutqvist and Sten Wingren
  p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients
  Pharmacogenetics and Genomics, 2006, 16(5), 347-351.
 Web of Science® Times Cited: 14

L Ryden, K Jirstrom, PA Bendahl, M Ferno, Bo Nordenskjöld, Olle Stål, Sten Thorstenson, PE Jonsson and G Landberg
  Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer
  Journal of Clinical Oncology, 2005, 23(21), 4695-4704.
 Web of Science® Times Cited: 53

Bo Nordenskjöld, Johan Rosell, Lars-Erik Rutqvist, Per-Olof Malmström, Jonas Bergh, Nils-Olof Bengtsson, Thomas Hatschek, Arne Wallgren and John Carstensen
  Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
  Journal of the National Cancer Institute, 2005, 97(21), 1609-1610.
 Web of Science® Times Cited: 37

K Jirström, L Rydén, L Anagnostaki, Bo Nordenskjöld, Olle Stål, S Thorstenson, G Chebil, P-E Jönsson, M Fernö and G Landberg
  Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
  Journal of Clinical Pathology, 2005, 58(11), 1135-1142.
 Web of Science® Times Cited: 26

Lisa Rydén, Per-Ebbe Jönsson, Gunilla Chebil, Monika Dufmats, Mårten Fernö, Karin Jirström, Ann-Christine Källström, Göran Landberg, Olle Stål, Sten Thorstenson and Bo Nordenskjöld
  Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up
  European Journal of Cancer, 2005, 41(2), 256-264.
 Web of Science® Times Cited: 54

Pia Wegman (Palmebäck), Linda Vainikka, Olle Stål, Bo Nordenskjöld, Lambert Skoog, Lars-Erik Rutqvist and Sten Wingren
  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
  Breast Cancer Research, 2005, 7(3), R284-R290.
   Fulltext  PDF  
 Web of Science® Times Cited: 119

Marie Ahnström Waltersson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.
  Breast Cancer Research and Treatment, 2005, 91(2), 145-151.
 Web of Science® Times Cited: 21

Marie Stenmark Askmalm, John Carstensen, Bo Nordenskjöld, Birgit Olsson, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients
  Acta Oncologica, 2004, 43(3), 235-244.
 Web of Science® Times Cited: 12

G Tejler, B Norberg, Monika Dufmats, Bo Nordenskjöld and Lars-Gunnar Arnesson
  Survival after treatment for breast cancer in a geographically defined population
  British Journal of Surgery, 2004, 91(10), 1307-1312.
 Web of Science® Times Cited: 11

Olle Stål, Gizeh Perez-Tenorio, Lind Åkerberg, Birgit Olsson, Bo Nordenskjöld, Lambert Skoog and Lars Rutqvist
  Akt kinases in breast cancer and the results of adjuvant therapy
  Breast Cancer Research, 2003, 5(2), R37-R44.
 Web of Science® Times Cited: 95

Cecilia Gunnarsson, Marie Ahnström, Kristina Kirschner, Birgit Olsson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Amplification of HSD17B1 and ERBB2 in primary breast cancer
  Oncogene, 2003, 22(1), 34-40.
 Web of Science® Times Cited: 52

Marie Sundquist, Sten Thorstenson, Lars Brudin, Sten Wingren and Bo Nordenskjöld
  Incidence and prognosis in early onset breast cancer
  Breast, 2002, 11(1), 30-35.
 Web of Science® Times Cited: 17

Lasse Karlsson, Anders Håkansson and Bo Nordenskjöld
  Opportunistisk cancerscreening i primärvård
  Läkartidningen, 2002, 99, 2636-2638.

Sören Mattsson, Anders Brahme, Jörgen Carlsson, Juliana Denekamp, Eva Forssell-Aronsson, Mikael Hellström, Karl-Axel Johansson, Elisabeth Kjellén, Bo Littbrand, Bo Nordenskjöld, Bo Stenerlöw, Ingela Turesson, Björn Zackrisson and Bengt Glimelius
  Swedish Cancer Society radiation therapy research investigation
  Acta Oncologica, 2002, 41(7-8), 596-603.
 Web of Science® Times Cited: 13

Bengt Glimelius, Bo Nordenskjöld, Elisabeth Kjellén and Björn Zackrisson
  Interactions between chemotherapy, endocrine therapy and radiation
  Acta Oncologica, 2002, 41(7-8), 635-638.
 Web of Science® Times Cited: 5

Lennarth Nyström, Ingvar Andersson, Nils Bjurstam, Jan Frisell, Bo Nordenskjöld and Lars Erik Rutqvist
  Long-term effects of mammography screening: Updated overview of the Swedish randomised trials
  The Lancet, 2002, 359(9310), 909-919.
 Web of Science® Times Cited: 524

L Carlsson, Annika Håkansson and Bo Nordenskjöld
  Common cancer-related symptoms among GP patients - Opportunistic screening in primary health care
  Scandinavian Journal of Primary Health Care, 2001, 19(3), 199-203.
 Web of Science® Times Cited: 9

Gunnar Adell, Hong Zhang, Agneta Jansson, Xiao-Feng Sun, Olle Stål and Bo Nordenskjöld
  Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer
  International Journal of Radiation Oncology, Biology, Physics, 2001, 50(3), 659-663.
 Web of Science® Times Cited: 29

Gunnar C. E. Adell, Hong Zhang, Sofia Evertsson, Xiao-Feng Sun, Olle Stål and Bo Nordenskjöld
  Apoptosis in rectal carcinoma: Prognosis and recurrence after preoperative radiotherapy
  Cancer, 2001, 91(10), 1870-1875.
 Web of Science® Times Cited: 31

Marie Sundquist, Sten Thorstenson, Lars Brudin, Olle Stål and Bo Nordenskjöld
  A comparison between flow cytometric assessment of S-phase fraction and Nottingham histologic grade as prognostic instruments in breast cancer
  Breast Cancer Research and Treatment, 2000, 63(1), 11-15.
 Web of Science® Times Cited: 5

Olle Stål, Å Borg, M Fernö, Ann-Christine Källström, P Malmström and Bo Nordenskjöld
  ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
  Annals of Oncology, 2000, 11(12), 1545-1550.
 Web of Science® Times Cited: 55

Marie Sundquist, Sten Thorstenson, Claes Klintenberg, Lars Brudin and Bo Nordenskjöld
  Indicators of loco-regional recurrence in breast cancer
  European Journal of Surgical Oncology, 2000, 26(4), 357-362.
 Web of Science® Times Cited: 12

Mårten Fernö, Olle Stål, Bo Baldetorp, Thomas Hatschek, Ann-Christine Källström, Per Malmström, Bo Nordenskjöld and Stefan Rydén
  Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
  Breast Cancer Research and Treatment, 2000, 59(1), 69-76.
 Web of Science® Times Cited: 47

Marie Sundquist, Sten Thorstenson, Lars Brudin and Bo Nordenskjöld
  Applying the Nottingham Prognostic Index to a Swedish breast cancer population
  Breast Cancer Research and Treatment, 1999, 53(1), 1-8.

Xiao-Feng Sun, Sabine Rütten, Hong Zhang and Bo Nordenskjöld
  Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma.
  Journal of Clinical Oncology, 1999, 17, 1745-1750.

Hong Zhang, Ahmad Ahmadi, G Arbman, J Zdolsek, J Carstensen, Bo Nordenskjöld, Peter Söderkvist and Xiao-Feng Sun
  Glutathione S-transferase T1 and M1 genotypes in normal mucosa, transitional mucosa and colorectal adenocarcinom.
  International Journal of Cancer, 1999, 84, 135-138.

Gunnar Adell, Xiao-Feng Sun, Olle Stål, Claes Klintenberg, Rune Sjödahl and Bo Nordenskjöld
  p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer.
  Radiotherapy and Oncology, 1999, 51(2), 169-174.

Hong Zhang, Bo Nordenskjöld, Monika Dufmats, Peter Söderkvist and Xiao-Feng Sun
  K-ras mutations in colorectal adenocarcinomas and neighbouring transitional mucosa.
  European Journal of Cancer, 1998, 34(13), 2053-2057.

Xiao-Feng Sun, Hanna Ekberg, Hong Zhang, John Carstensen and Bo Nordenskjöld
  Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma
  Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS), 1998, 106(6), 657-664.

Xiao-Feng Sun, Hong Zhang, John Carstensen, Agneta Jansson and Bo Nordenskjöld
  Heat shock protein 72/73 in relation to cytoplasmic p53 expression and prognosis in colorectal adenocarcinomas
  International Journal of Cancer, 1997, 74(6), 600-604.
 Web of Science® Times Cited: 28

Conference Articles

Piiha-Lotta Jerevall, A. Jansson, T. Fornander, L. Skoog, Bo Nordenskjöld and Olle Stål
  HOXB13 protein expression predicts the benefit of tamoxifen treatment in breast cancer patients: in CANCER RESEARCH, vol 69, issue 2, Supplement 1, pp 358S-358S
  CANCER RESEARCH, 2009.


A Di Leo, P Francis, J P Crown, Azambuja E de, E Quinaux, J Gutierrez, Bo Nordenskjöld, M Andersson, Vila M Margeli, M Piccart-Gebhart, R Jakesz, G Viale and S R Olsen
  Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial in CANCER RESEARCH, vol 69, issue 24, pp 521S-521S
  CANCER RESEARCH, 2009.


Tove Sivik, Olle Stål, T Fornander, L Skoog, Bo Nordenskjöld and Agneta Jansson
  Significance of 17bHSD Type 14 as a Predictive Factor for Adjuvant Tamoxifen Treatment Response in Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 596S-597S
  CANCER RESEARCH, 2009.


MA Waltersson, E Karlsson, Bo Nordenskjöld, T Fornander, L Skoog and Olle Stål
  miR-206 Expression Is Downregulated in Cyclin D1 Amplified Breast Tumours. in CANCER RESEARCH, vol 69, issue 24, pp 579S-579S
  CANCER RESEARCH, 2009.


Josefine Bostner, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stal
  Estrogen Receptor alpha Phosphorylation on Serine 305, p21-Activated Kinase 1 and Tamoxifen Response in Postmenopausal Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 596S-596S
  CANCER RESEARCH, 2009.


* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.